Therapeutic Response

HER2-negative status confers therapeutic sensitivity to Capecitabine in combination with Oxaliplatin and Pembrolizumab in patients with Adenocarcinoma of the Gastroesophageal Junction.

Statements

Source and description

Keytruda (pembrolizumab) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma. This indication is based on KEYNOTE-859 (NCT03675737), a multicenter, randomized, double-blind, placebo-controlled trial where patients received investigator's choice of combination chemotherapy of either cisplatin and 5-fu or oxaliplatin and capecitabine.